Feed Symbols: OCUL

Ocular Therapeutix (NASDAQ:OCUL) brought in sales totaling $13.19 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 225.77%, resulting in a loss of $12.54 million.

  During Friday's session, 59 stocks hit new 52-week lows.

  On Thursday, 94 companies set new 52-week lows.

Over the past 3 months, 4 analysts have published their opinion on Ocular Therapeutix (NASDAQ:OCUL) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.26) by 15.38 percent. This is a 8.33 percent increase over losses of $(0.24) per share from

  Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.

Gainers Ocular Therapeutix (NASDAQ:OCUL) shares moved upwards by 12.3% to $4.01 during Friday's after-market session. The company's market cap stands at $307.7 million.

  On Friday =, 431 companies hit new 52-week lows.

  On Wednesday, 160 companies hit new 52-week lows.

Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting season.